Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection

Lauren Cherrier, Aasya Nasar, Kellie J. Goodlet, Michael D. Nailor, Sofya Tokman, Sunwen Chou

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Following a year of valganciclovir prophylaxis, a lung transplant recipient developed cytomegalovirus (CMV) infection that became resistant to ganciclovir, as confirmed by detection of UL97 kinase mutation M460V and a previously uncharacterized UL54 DNA polymerase mutation L516P. The latter mutation is now shown to confer ganciclovir and cidofovir resistance. As predicted from the viral genotype, foscarnet therapy was effective, but resumption of valganciclovir as secondary prophylaxis resulted in a plasma viral load rebound to 3.6 log10 copies/mL several weeks later. Valganciclovir was then replaced by letermovir, resulting in gradual viral load reduction in the first 5 weeks to below the quantitation limit (2.7 log10 copies/mL) for 1 week, followed by 10 weeks of rising viral loads reaching 4.3 log10 copies/mL while on letermovir. At this point, CMV genotypic testing revealed UL56 mutation C325Y, which confers absolute resistance to letermovir. Retreatment with foscarnet was successful. This case adds to the considerable list of proven ganciclovir resistance mutations, and provides an early experience with letermovir resistance after off-label therapeutic use. This experience is consistent with in vitro observations of rapid emergence of letermovir-resistant CMV after drug exposure.

Original languageEnglish (US)
JournalAmerican Journal of Transplantation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Ganciclovir
Cytomegalovirus Infections
Lung
Mutation
Viral Load
Foscarnet
Cytomegalovirus
Off-Label Use
Retreatment
Therapeutic Uses
DNA-Directed DNA Polymerase
Phosphotransferases
Genotype
AIC246
Transplant Recipients
Pharmaceutical Preparations
valganciclovir

Keywords

  • antibiotic: antiviral
  • antibiotic: antiviral-ganciclovir/valganciclovir
  • clinical research/practice
  • infection and infectious agents - viral: Cytomegalovirus (CMV)
  • infectious disease
  • off-label drug use
  • translational research/science

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. / Cherrier, Lauren; Nasar, Aasya; Goodlet, Kellie J.; Nailor, Michael D.; Tokman, Sofya; Chou, Sunwen.

In: American Journal of Transplantation, 01.01.2018.

Research output: Contribution to journalArticle

@article{8442b4f8f1564c0fbf016f5a5c33402b,
title = "Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection",
abstract = "Following a year of valganciclovir prophylaxis, a lung transplant recipient developed cytomegalovirus (CMV) infection that became resistant to ganciclovir, as confirmed by detection of UL97 kinase mutation M460V and a previously uncharacterized UL54 DNA polymerase mutation L516P. The latter mutation is now shown to confer ganciclovir and cidofovir resistance. As predicted from the viral genotype, foscarnet therapy was effective, but resumption of valganciclovir as secondary prophylaxis resulted in a plasma viral load rebound to 3.6 log10 copies/mL several weeks later. Valganciclovir was then replaced by letermovir, resulting in gradual viral load reduction in the first 5 weeks to below the quantitation limit (2.7 log10 copies/mL) for 1 week, followed by 10 weeks of rising viral loads reaching 4.3 log10 copies/mL while on letermovir. At this point, CMV genotypic testing revealed UL56 mutation C325Y, which confers absolute resistance to letermovir. Retreatment with foscarnet was successful. This case adds to the considerable list of proven ganciclovir resistance mutations, and provides an early experience with letermovir resistance after off-label therapeutic use. This experience is consistent with in vitro observations of rapid emergence of letermovir-resistant CMV after drug exposure.",
keywords = "antibiotic: antiviral, antibiotic: antiviral-ganciclovir/valganciclovir, clinical research/practice, infection and infectious agents - viral: Cytomegalovirus (CMV), infectious disease, off-label drug use, translational research/science",
author = "Lauren Cherrier and Aasya Nasar and Goodlet, {Kellie J.} and Nailor, {Michael D.} and Sofya Tokman and Sunwen Chou",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/ajt.15135",
language = "English (US)",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection

AU - Cherrier, Lauren

AU - Nasar, Aasya

AU - Goodlet, Kellie J.

AU - Nailor, Michael D.

AU - Tokman, Sofya

AU - Chou, Sunwen

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Following a year of valganciclovir prophylaxis, a lung transplant recipient developed cytomegalovirus (CMV) infection that became resistant to ganciclovir, as confirmed by detection of UL97 kinase mutation M460V and a previously uncharacterized UL54 DNA polymerase mutation L516P. The latter mutation is now shown to confer ganciclovir and cidofovir resistance. As predicted from the viral genotype, foscarnet therapy was effective, but resumption of valganciclovir as secondary prophylaxis resulted in a plasma viral load rebound to 3.6 log10 copies/mL several weeks later. Valganciclovir was then replaced by letermovir, resulting in gradual viral load reduction in the first 5 weeks to below the quantitation limit (2.7 log10 copies/mL) for 1 week, followed by 10 weeks of rising viral loads reaching 4.3 log10 copies/mL while on letermovir. At this point, CMV genotypic testing revealed UL56 mutation C325Y, which confers absolute resistance to letermovir. Retreatment with foscarnet was successful. This case adds to the considerable list of proven ganciclovir resistance mutations, and provides an early experience with letermovir resistance after off-label therapeutic use. This experience is consistent with in vitro observations of rapid emergence of letermovir-resistant CMV after drug exposure.

AB - Following a year of valganciclovir prophylaxis, a lung transplant recipient developed cytomegalovirus (CMV) infection that became resistant to ganciclovir, as confirmed by detection of UL97 kinase mutation M460V and a previously uncharacterized UL54 DNA polymerase mutation L516P. The latter mutation is now shown to confer ganciclovir and cidofovir resistance. As predicted from the viral genotype, foscarnet therapy was effective, but resumption of valganciclovir as secondary prophylaxis resulted in a plasma viral load rebound to 3.6 log10 copies/mL several weeks later. Valganciclovir was then replaced by letermovir, resulting in gradual viral load reduction in the first 5 weeks to below the quantitation limit (2.7 log10 copies/mL) for 1 week, followed by 10 weeks of rising viral loads reaching 4.3 log10 copies/mL while on letermovir. At this point, CMV genotypic testing revealed UL56 mutation C325Y, which confers absolute resistance to letermovir. Retreatment with foscarnet was successful. This case adds to the considerable list of proven ganciclovir resistance mutations, and provides an early experience with letermovir resistance after off-label therapeutic use. This experience is consistent with in vitro observations of rapid emergence of letermovir-resistant CMV after drug exposure.

KW - antibiotic: antiviral

KW - antibiotic: antiviral-ganciclovir/valganciclovir

KW - clinical research/practice

KW - infection and infectious agents - viral: Cytomegalovirus (CMV)

KW - infectious disease

KW - off-label drug use

KW - translational research/science

UR - http://www.scopus.com/inward/record.url?scp=85055718781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055718781&partnerID=8YFLogxK

U2 - 10.1111/ajt.15135

DO - 10.1111/ajt.15135

M3 - Article

C2 - 30286286

AN - SCOPUS:85055718781

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

ER -